Impel NeuroPharma Inc. (IMPL) Files Chapter 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- S&P 500, Nasdaq futures edge higher ahead of Fed decision; chip stocks wobble
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Oil rises as US-Iran tension escalates after Iraq strikes, missile attack
- Procter & Gamble falls on weak sales, cautious guidance
- Vertiv shares sink as Q2 revenue miss offsets upgraded guidance
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- S&P 500 ends higher as investors await tech earnings
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale
December 19, 2023 11:10 PM ESTPatient Access to Trudhesa® to Continue Uninterrupted
Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process
SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the... More
